Malignant mesenchymoma of the uterus, arising in a leiomyoma.
OBJECTIVE
To document and find evidence for the rare occurrence of malignant progression of a benign uterine leiomyoma with divergent mesenchymal differentiation. In a 54-year-old female a large pedunculated tumour was encountered which had suddenly increased in size and had apparently arisen at the site of a subserosal uterine leiomyoma first described 19 years earlier. The tumour seemed histologically diverse in its composition. The possibility of malignant progression of the benign leiomyoma with divergent mesenchymal differentiation was entertained.


RESULTS
In the resected tumour, smooth muscle, osseous and adipose components were identified and these were assessed using recognized histological criteria of malignancy. In addition to a benign smooth muscle component, malignant leiomyosarcomatous tissue was seen in addition to a malignant osseous component and a malignant adipose component. The tumour thus met the criteria of a malignant mesenchymoma. The relationship of the different components of the tumour was analysed by immunohistochemistry and with molecular loss of heterozygosity (LOH) analysis. In the osseous and leiomyosarcomatous components a similar LOH pattern was observed. The adipose component showed a distinct LOH pattern. Retention of smooth muscle differentiation in the osseous component was demonstrated by desmin immunostaining.


CONCLUSIONS
Malignant transformation of benign uterine leiomyoma may rarely occur. Mesenchymal stem cells underlying these tumours may show divergent mesenchymal differentiation.
den Bakker
M A
MA
Stichting Laboratorium Pathologie en Cytologie (PATHAN), St Franciscus Gasthuis, Erasmus Medical Care Rotterdam, Rotterdam, The Netherlands. michael.denbakker@rcht.swest.nhs.uk
Hegt
V Noordhoek
VN
Sleddens
H B F M
HB
Nuijten
A S M
AS
Dinjens
W N M
WN
D000273:Adipose Tissue / Q000473:pathology; D014408:Biomarkers, Tumor / Q000032:analysis; D004273:DNA, Neoplasm / Q000032:analysis; D003893:Desmin / Q000032:analysis; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D007889:Leiomyoma / Q000737:chemistry / Q000235:genetics / Q000473:pathology*; D019656:Loss of Heterozygosity; D008637:Mesenchymoma / Q000737:chemistry / Q000235:genetics / Q000556:secondary*; D008875:Middle Aged; D016609:Neoplasms, Second Primary / Q000473:pathology*; D012516:Osteosarcoma / Q000737:chemistry / Q000235:genetics / Q000556:secondary; D016133:Polymerase Chain Reaction; D014057:Tomography, X-Ray Computed; D014594:Uterine Neoplasms / Q000737:chemistry / Q000235:genetics / Q000473:pathology*
D014408:Biomarkers, Tumor; D004273:DNA, Neoplasm; D003893:Desmin